View Item 

Show simple item record

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation
dc.contributor.authorChey, William D.en_US
dc.contributor.authorDrossman, D. A.en_US
dc.contributor.authorJohanson, J. F.en_US
dc.contributor.authorScott, C.en_US
dc.contributor.authorPanas, R. M.en_US
dc.contributor.authorUeno, R.en_US
dc.date.accessioned2012-03-16T15:57:43Z
dc.date.available2013-05-01T17:24:40Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationChey, W. D.; Drossman, D. A.; Johanson, J. F.; Scott, C.; Panas, R. M.; Ueno, R. (2012). "Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation." Alimentary Pharmacology & Therapeutics 35(5): 587-599. <http://hdl.handle.net/2027.42/90244>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90244
dc.publisherWiley Periodicals, Inc.en_US
dc.titleSafety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22251419en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90244/1/apt4983.pdf
dc.identifier.doi10.1111/j.1365-2036.2011.04983.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceLongstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480 – 91.en_US
dc.identifier.citedreferenceBrandt LJ, Chey WD, Foxx‐Orenstein AE, et al. An evidence‐based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 ( Suppl. 1 ): S1 – 35.en_US
dc.identifier.citedreferenceSaito YA., Locke GR., Talley NJ., et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 2816 – 24.en_US
dc.identifier.citedreferenceSaito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910 – 5.en_US
dc.identifier.citedreferenceQuander C, Morris MC, Bienias JL, Evans DA. Prevalence of irritable bowel syndrome in an older bi‐racial population [Abstract 1085]. Am J Gastroenterol 2007; 102: S516.en_US
dc.identifier.citedreferenceLocke GR., Clark S., Cerulli A., et al. Work productivity is more impaired in functional gastrintestinal disorders compared to GERD: six‐month data from PROGRESS [abstract 1052]. Am J Gastroenterol 2007; 102: S504.en_US
dc.identifier.citedreferenceDrossman DA., Chey WD., Panas R., et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS‐C): data from two, twelve‐week, randomized, placebo‐controlled, double blind trials [abstract]. Gastroenterology 2007; 132: 639f.en_US
dc.identifier.citedreferenceDrossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies. Aliment Pharmacol Ther 2009; 29: 329 – 41.en_US
dc.identifier.citedreferenceDrossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS‐QOL: a disease‐specific quality‐of‐life questionnaire. Am J Gastroenterol 2000; 95: 999 – 1007.en_US
dc.identifier.citedreferencePatrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400 – 11.en_US
dc.identifier.citedreferenceGuo Z, Gill TM, Allore HG. Modeling repeated time‐to‐event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med 2008; 47: 107 – 16.en_US
dc.identifier.citedreferenceCamilleri M, Bharaucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942 – 7.en_US
dc.identifier.citedreferenceCuppoletti J, Malinowska DH, Tewari KP, et al. SPI‐0211 activates T84 cell chloride transport and recombinant human ClC‐2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C1178 – 83.en_US
dc.identifier.citedreferenceMoeser AJ., Nighot PK., Engelke KJ., Ueno R, Blikslager AT. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC‐2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007; 292: G647 – 56.en_US
dc.identifier.citedreferenceCamilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 545 – 52.en_US
dc.identifier.citedreferenceJohanson JF, Morton D, Geenen J, Ueno R. Multicenter, four‐week, double‐blind, randomized, placebo‐controlled trial of lubiprostone, a locally‐acting type‐2 chloride channel activator in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170 – 7.en_US
dc.identifier.citedreferenceJohanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685 – 96.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt4983.pdf
Size:
575.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.